Evidence map›Paper›PMID 23392455›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2013

Polymorphisms of the kappa opioid receptor and prodynorphin genes: HIV risk and HIV natural history.

Dmitri Proudnikov, Matthew Randesi, Orna Levran, Vadim Yuferov, Howard Crystal, Ann Ho, Jurg Ott, Mary J Kreek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Opioid and neuroHIV Comorbidity - Current and Future Perspectives.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dmitri ProudnikovLaboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10065, USA. dmitri_proudnikov@hotmail.com
Matthew Randesi
Orna Levran
Vadim Yuferov
Howard Crystal
Ann Ho
Jurg Ott
Mary J Kreek
Rockefeller University · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
ULTRASTUCTURE, RECEPTORS, AND GENE EXPRESSIONP60DA005130 · NIDA · ROCKEFELLER UNIVERSITY · PI KREEK, MARY J · 2002 to 2012
$30.6M
UNIQUE RNA STRUCTURE OF CAUSATIVE AGENT FOR DELTA HEPATITISP50DA005130 · NIDA · ROCKEFELLER UNIVERSITY · PI KREEK, MARY J · 1987 to 2001
$5.0M
HIV and Psychiatric Comorbidity: Selected Genetic and Epigenetic FactorsR01MH079880 · NIMH · ROCKEFELLER UNIVERSITY · PI KREEK, MARY J · 2006 to 2010
$3.0M
Substance Abuse and HIV: Genetics &Disease ProgressionR01MH076537 · NIMH · SUNY DOWNSTATE MEDICAL CENTER · PI CRYSTAL, HOWARD A · 2005 to 2009
$2.2M
NCRR NIH HHS UL1 RR024131NIAID NIH HHS AI-35004NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS UO1-AI-31834NIAID NIH HHS UO1-AI-34989NIAID NIH HHS UO1-AI-34993NIAID NIH HHS UO1-AI-34994NIAID NIH HHS UO1-AI-42590NICHD NIH HHS U01 HD032632NICHD NIH HHS UO1-HD-32632NIDA NIH HHS P50 DA005130NIDA NIH HHS P60 DA005130NIDA NIH HHS P60-DA05130NIMH NIH HHS MH79880NIMH NIH HHS R01 MH076537NIMH NIH HHS R01 MH079880
6 · The paper itself

Abstract

objectiveStudies indicate cross-desensitization between opioid receptors (eg, kappa opioid receptor, OPRK1) and chemokine receptors (eg, CXCR4) involved in HIV infection. Whether gene variants of OPRK1 and its ligand, prodynorphin (PDYN), influence the outcome of HIV therapy was tested.

methodsThree study points, admission to the Women's Interagency HIV Study, initiation of highly active antiretroviral therapy (HAART), and the most recent visit, were chosen for analysis as crucial events in the clinical history of the HIV patients. Regression analyses of 17 variants of OPRK1 and 11 variants of PDYN with change of viral load (VL) and CD4 count between admission and initiation of HAART and initiation of HAART to the most recent visit to Women's Interagency HIV Study were performed in 598 HIV+ subjects, including African Americans, Hispanics, and Whites. Association with HIV status was done in 1009 subjects.

resultsBefore HAART, greater VL decline (improvement) in carriers of PDYN IVS3+189C>T and greater increase of CD4 count (improvement) in carriers of OPRK -72C>T were found in African Americans. Also, greater increase of CD4 count in carriers of OPRK1 IVS2+7886A>G and greater decline of CD4 count (deterioration) in carriers of OPRK1 -1205G>A were found in Whites. After HAART, greater decline of VL in carriers of OPRK1 IVS2+2225G>A and greater increase of VL in carriers of OPRK1 IVS2+10658G>T and IVS2+10963A>G were found in Whites. Also, a lesser increase of CD4 count was found in Hispanic carriers of OPRK1 IVS2+2225G>A.

conclusionsOPRK1 and PDYN polymorphisms may alter severity of HIV infection and response to treatment.

Indexed as

Antiretroviral Therapy, Highly ActiveBlack or African AmericanCD4 Lymphocyte CountHispanic or LatinoHIV-1HIV InfectionsHumansPolymorphism, Single NucleotidePrognosisReceptors, CXCR4Receptors, Opioid, kappaRisk FactorsTreatment OutcomeViral LoadWhite PeopleCXCR4 protein, humanOPRK1 protein, humanReceptors, CXCR4Receptors, Opioid, kappa

Identifiers

PMID23392455
PMCPMC3625517
OpenAlexW2046805586

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.